Search Results
Your search for The A,The A matches 32372 pages
Showing 12151 - 12200Expert Point of View: Navid Hafez, MD, MPH
Ilixadencel is essentially a dendritic cell vaccine without preloaded antigens. In the MERECA study, ilixadencel produced “a great signal,” though this approach is still very experimental, said the study’s invited discussant, Navid Hafez, MD, MPH, of Yale Cancer Center. Dr. Hafez is a member of the ...
Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer
Ilixadencel is a cell-based, allogeneic, off-the-shelf product aimed at priming the anticancer immune response when injected intratumorally. The phase II MERECA study evaluated this allogeneic dendritic cell product given with sunitinib in 88 patients with metastatic renal cell carcinoma. The study ...
Study Examines Survival Rates in Pediatric and Young Adult Patients With Colon Cancer
According to research published by Andrea Hayes-Jordan, MD, FACS, and colleagues in the Journal of the American College of Surgeons, children and young adults with colon cancer are more likely to have shorter overall survival and recurrence-free survival than middle-aged adults. In a...
Evaluation of Different Methods of Biopsy for the Diagnosis of Prostate Cancer
In a study reported in The New England Journal of Medicine, Ahdoot et al found that combined use of magnetic resonance imaging (MRI)-targeted biopsy and 12-core systematic prostate biopsy led to enhanced detection of prostate cancers vs either approach alone in men with MRI-visible prostate...
Prognostic Value of Teratoma in Metastatic Nonseminomatous Germ Cell Tumor
In a single-institution retrospective study reported in the Journal of Clinical Oncology, Taza et al found that the presence of teratoma in primary tumor and postchemotherapy retroperitoneal lymph node dissection specimens was not a prognostic factor in patients with metastatic testicular germ cell ...
First-Line Cladribine With Concurrent or Delayed Rituximab for Hairy Cell Leukemia
In a phase II study reported in the Journal of Clinical Oncology, Robert J. Kreitman, MD, and colleagues found that achievement of minimal residual disease–free complete remission for patients with hairy cell leukemia was enhanced by adding concurrent rituximab to first-line cladribine; a lesser...
Help Patients Do More to Cope With Cancer-Related Pain
Relieving pain is an important part of cancer care, and each patient experiences pain differently. ASCO Answers offers two helpful products for managing cancer-related pain: a one-page fact sheet and an in-depth booklet. These resources help patients and their caregivers learn about: The...
QOPI Round 1 Now Open for Data Abstraction: Improve Quality Practice-Wide
ASCO’s Quality Oncology Practice Initiative (QOPI®) Round 1 of reporting is open for data abstraction. Round 1 will close on June 5, 2020, and final reports will be available approximately 4 weeks later. To get started, go to the registration portal at myqopi.asco.org/registration/login.aspx and...
Roles Are Reversed in ‘Personalized Medicine’ as Physicians Care for Parents With Cancer
As early-career oncologists, Rachna Shroff, MD, and Nina Shah, MD, offered patients a textbook bedside manner—personal interactions were limited, and emotions were rarely shared. “People talk about how, especially in oncology, the more you let [a patient] in, the more profoundly you feel losses,...
Medicaid Block Grants Threaten Beneficiary Access to Cancer Care
ASCO has released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” summarizing the Society’s concerns about the potential negative impact that block grants—proposals that establish annual limits on federal funding for Medicaid—could have on patients with cancer....
Conquer Cancer Honors Early-Career Cancer Researchers With Merit Awards
ASCO and Conquer Cancer, the ASCO Foundation®, congratulate the recipients of recent Conquer Cancer Merit Awards, which recognize oncology fellows’ and trainees’ high-quality research submitted in abstracts to an ASCO-sponsored or cosponsored meeting. These early-career researchers presented their...
Thirty-Three Oncology Practices Receive QOPI Certification From the Association for Clinical Oncology
Thirty-three practices received the Quality Oncology Practice Initiative (QOPI®) certification in the fourth quarter of 2019. The Association for Clinical Oncology applauds the work of these practices to ensure a better and healthier future. The following practices achieved QOPI certification or...
Conquer Cancer–Funded Researcher’s Pancreatic Cancer Study Highlighted in ASCO’s Clinical Cancer Advances 2020
The work of nine researchers who have previously received funding from Conquer Cancer is featured in ASCO’s Clinical Cancer Advances 2020. Visit CONQUER.ORG for more details. Advance of the Year: Refinement of Surgical Treatment At Massachusetts General Hospital, Janet Murphy, MD, is expanding...
Therapy Is Keeping My Metastatic Breast Cancer Manageable
Despite being vigilant about adhering to my annual schedule of screening mammography, in 2002, I was diagnosed with stage III triple-negative breast cancer. The diagnosis scared me, and I wondered if I was going to die. Determined to do what I could to survive the cancer, I underwent aggressive...
Susan Band Horwitz, PhD, Named Recipient of 2020 Szent-Györgyi Prize
The National Foundation for Cancer Research (NFCR) recently announced that Susan Band Horwitz, PhD, has been selected to receive the 2020 Szent-Györgyi Prize for Progress in Cancer Research. Dr. Horwitz is being recognized for pioneering the understanding, at the molecular level, of the mechanisms...
Reflections on a Career in Hematology/Oncology
I am a retired 82-year-old Hematologist/Oncologist who reads The ASCO Post regularly. I am writing to share some brief thoughts with the authors of two articles in the February 10, 2020 issue. First, I would address the article, A Hopeful Look Ahead in Oncology, written by Dan L. Longo, MD, MACP....
Building Onco-Primary Care to Close the ‘Black Hole’ in Cancer Survivorship Care
When the landmark report from the Institute of Medicine, From Cancer Patient to Cancer Survivor: Lost in Transition, was published in 2006, there were 10 million cancer survivors in the United States.1 Meant to raise awareness of the medical, functional, and psychosocial consequences of a cancer...
Former ASCO President Sandra M. Swain, MD, FACP, FASCO, Shares Highlights of a Noted Career
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Sandra M. Swain, MD, FACP, FASCO, Professor of Medicine and Associate Dean for Research Development at Georgetown University Medical Center, and Vice President of MedStar Genetic Medicine at Medstar...
Attempt to Transform Venipuncture: A Brilliant Idea Made From Smoke and Mirrors
Venipuncture is the most commonly performed invasive procedure in hospitals daily. The risk of this procedure is nerve damage or an arterial nick. Of course, there are other possible issues, such as hematoma and injection-site infection. Then there’s dealing with caterwauling children and swooning...
Tazemetostat for Advanced Epithelioid Sarcoma
On January 23, 2020, tazemetostat was granted accelerated approval for the treatment of adults and pediatric patients aged 16 and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.1,2 Supporting Efficacy Data Approval was based on the finding of...
NCI Awards $9.1 Million Grant to Cedars-Sinai for Research on Dietary Fat and Liver Metastasis
A scientific team has been awarded a $9.1 million grant by the National Cancer Institute to study liver metastasis. The co-lead investigators, Neil Bhowmick, PhD, Director of the Cancer Biology Program, and Shelly Lu, MD, Women’s Guild Chair in Gastroenterology and Director of the Division of...
Selected ASH Abstracts on Novel Treatments in Acute Lymphoblastic Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed and relapsed or refractory acute...
Avapritinib for Gastrointestinal Stromal Tumor With PDGFRA Exon 18 Mutation
On January 9, 2020, avapritinib was approved for treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations.1,2 It is the first therapy approved for...
21-Gene Assay Recurrence Score and Risk of Locoregional Recurrence in Hormone Receptor–Positive, Node-Positive Breast Cancer
A retrospective analysis from the Southwest Oncology Group S8814 trial, reported by Wendy A. Woodward, MD, PhD, of the Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, and colleagues in JAMA Oncology,1 showed that a low 21-gene assay recurrence score was...
Brief Highlights From the 2019 San Antonio Breast Cancer Symposium
In addition to our regular coverage of the 2019 San Antonio Breast Cancer Symposium, the following reports from the meeting include studies you may have missed. We hope you find them of interest. Ribociclib/Letrozole as Neoadjuvant Therapy As neoadjuvant therapy in women with high-risk hormone...
Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer
Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast...
Smilow Cancer Hospital and Yale Cancer Center to Welcome Pamela L. Kunz, MD
PAMELA L. KUNZ, MD, has been appointed Leader of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center and Director of GI Medical Oncology within the Section of Medical Oncology. Dr. Kunz joins Yale from Stanford University School of Medicine in...
H. Timothy Hsiao, PhD, Joins the American Society for Radiation Oncology as Director of Scientific Affairs
The American Society for Radiation Oncology (ASTRO) recently welcomed H. Timothy Hsiao, PhD, as its new Director of Scientific Affairs, where he will provide strategic leadership to advance the impact of research and innovation in radiation oncology through ASTRO’s research funding, fellowships,...
Expert Point of View: James N. Gerson, MD
James N. Gerson, MD, Assistant Professor of Medicine at Perelman School of Medicine, University of Pennsylvania, Philadelphia, commented on the implications of the findings from CAPTIVATE. “Upfront therapy for chronic lymphocytic leukemia (CLL) is rapidly evolving. We now have three...
Oral Regimen of Ibrutinib/Venetoclax Achieves High Rates of Undetectable Minimal Residual Disease in CLL
Updated results of the phase II CAPTIVATE trial continue to show high response rates as well as high rates of undetectable minimal residual disease (MRD) with ibrutinib plus venetoclax as front-line treatment of chronic lymphocytic leukemia (CLL) in patients under the age of 70 years. The...
Treating Patients With Chronic Lymphocytic Leukemia in 2020
With the availability of a number of effective targeted agents for the treatment of chronic lymphocytic leukemia (CLL), the question arises whether chemotherapy still has a role in treating this malignancy. At the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, CLL...
Expert Point of View: Javier Pinilla-Ibarz, MD, PhD
Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center, Tampa, Florida, commented on this study: “ELEVATE TN compared front-line treatment with acalabrutinib alone or in combination with obinutuzumab vs obinutuzumab/chlorambucil and showed that a second-generation Bruton’s tyrosine kinase (BTK)...
Acalabrutinib Plus Obinutuzumab Superior to Obinutuzumab Plus Chlorambucil as Front-Line Treatment of CLL
Ibrutinib was the first Bruton’s tyrosine kinase (BTK) inhibitor to dramatically transform the treatment of patients with chronic lymphocytic leukemia (CLL) and other hematologic malignancies. The second-generation BTK inhibitor acalabrutinib is a more selective BTK inhibitor designed to have an...
Translational Research in Oncology Appoints Peter Fasching, MD, and Hari Kumar, PhD, to Board of Directors
TRANSLATIONAL RESEARCH IN ONCOLOGY (TRIO), a global academic clinical research organization, recently announced the appointment of two new members to the Company’s Board of Directors. Joining the board are Peter Fasching, MD, and Hari Kumar, PhD. Together, they bring decades of leadership in key...
Rush University Medical Center Earns National Center of Excellence for Pancreatic Cancer Designation
The National Pancreas Foundation has named Rush University Medical Center as a National Center of Excellence for Pancreatic Cancer, a designation given to hospitals that have demonstrated the multidisciplinary approach, social support, and advanced research resources needed to successfully treat...
Expert Point of View: Charles G. Drake, MD, PhD
In an interview with The ASCO Post, Charles G. Drake, MD, PhD, expounded on the results of the COSMIC-021 trial. Dr. Drake is Division Director for GU Oncology, Co-Director of the Cancer Immunotherapy Program, and Co-Leader of the Tumor Biology and Microenvironment Program at the Herbert Irving...
Novel Combination of Cabozantinib Plus Atezolizumab Shows Benefit in Patients With Advanced Prostate Cancer
The combination of the small-molecule tyrosine kinase inhibitor cabozantinib (inhibits VEGF, AXL, MET, and others), plus the immune checkpoint inhibitor atezolizumab achieved encouraging activity in patients with metastatic castration-resistant prostate cancer, according to the results of...
Expert Point of View: Richard L. Schilsky, MD, FACP, FSCT, FASCO
Richard L. Schilsky, MD, FACP, FSCT, FASCO, ASCO’s Chief Medical Officer and a gastrointestinal oncologist himself, was pleased to see the TAPUR study bearing fruit among patients with metastatic colorectal cancer. “Colorectal cancer is a very common disease, but we have not made much progress in...
ASCO’s TAPUR Study: Biomarker-Driven Treatment Paying Off in Colorectal Cancer
New data presented at the 2020 Gastrointestinal Cancers Symposium are validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study, a multibasket trial that matches patients’ genomic alterations to commercially available targeted therapies. The aim is to learn...
Richard L. Schilsky, MD, FACP, FSCT, FASCO, Designated a National Associate of the National Academies of Sciences, Engineering, and Medicine
In February 2020, Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, was designated a National Associate of the National Academy of Sciences, Engineering, and Medicine for his decades-long contributions to the National Academy of Medicine (NAM). ...
ASCO and CAP Release Updated Guideline on Estrogen and Progesterone Testing in Breast Cancer
ASCO and the College of American Pathologists (CAP) have jointly published an update to a clinical practice guideline on estrogen receptor and progesterone receptor testing in breast cancer.1 The guideline for immunohistochemistry testing of estrogen receptor and progesterone receptors in patients...
An Education in Human Suffering
By way of tradition, our current system of oncology training exposes fellows to vast amounts of suffering in their first year. As fellows, we see dying patients with cancer in the hospital; we see the third-opinion, last-ditch referrals; we see most newly presenting patients; and we spend the hours ...
Expert Point of View: Daniel Geynisman, MD
Formal discussant of this trial of MK-6482, Daniel Geynisman, MD, of Fox Chase Cancer Center, Philadelphia, was enthusiastic about this presentation. “The response rates were fabulous in this group of heavily pretreated patients,” he stated. “A total of 69% had some tumor shrinkage, 24% had an...
MK-6482 Shows Activity Across All Risk Categories in Metastatic Clear Cell Kidney Cancer
A novel approach using a drug called MK-6482 showed activity in a phase I/II study in patients with metastatic clear cell renal cell carcinoma, according to a presentation at the 2020 Genitourinary Cancers Symposium.1 MK-6482 is an oral, first-in-class selective small-molecule inhibitor that...
Tumor Mutation Burden Testing
Vamsi Velcheti, MD, and David Rimm, MD, PhD, discuss the recent clinical trials that studied tumor mutation burden (TMB) as a biomarker and the mechanisms behind why tumors with high TMB respond to immunotherapy.
PD-L1 Expression Testing
Vamsi Velcheti, MD, and David Rimm, MD, PhD, discuss the high number of recent programmed death ligand 1 (PD-L1) inhibitor approvals and the need to harmonize the various diagnostic assay developments across the supporting clinical trials. Dr. Rimm notes the important difference between companion...
Expert Point of View: Jarushka Naidoo, MBBCh
“The investigators of the current study tested the hypothesis that vitamin D supplementation is associated with a reduced risk of checkpoint-induced colitis by rigorously assessing 37 variables in both discovery and validation cohorts,” said invited discussant Jarushka Naidoo, MBBCh, Assistant...
Vitamin D Supplementation May Protect Against Checkpoint Inhibitor–Induced Colitis
Vitamin D supplementation prior to starting immune checkpoint inhibitor therapy may significantly reduce the odds of developing colitis, according to a study conducted at Harvard Medical School. Although this was a retrospective chart review, the association was relatively strong in the...
Expert on Public Health and Policy Looks at Precision Oncology
A study published in JAMA Oncology found that 31 genome-targeted anticancer agents were in use as of January 2018.1 To shed light on the current state of precision oncology, The ASCO Post recently spoke with David M. Cutler, PhD, the Otto Eckstein Professor of Applied Economics in the Department of ...
FDA Pipeline: Priority Review in DLBCL, Fast Track Designations in T-Cell Lymphoma and Adenoid Cystic Carcinoma
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to a combination therapy in diffuse large B-cell lymphoma (DLBCL); gave Fast Track designations for treatments in T-cell lymphoma and adenoid cystic carcinoma; granted Orphan Drug designation to an agent for the ...
